2011
A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome.
Mehnert J, Mortazavi A, Stein M, Donadio A, Zelterman D, McDonough J, Rowen E, Hoimes C, Gibney G, Kelly W. A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Journal Of Clinical Oncology 2011, 29: 278-278. DOI: 10.1200/jco.2011.29.7_suppl.278.Peer-Reviewed Original ResearchTransitional cell carcinomaAdvanced transitional cell carcinomaPR/CRDose reductionOral tyrosine kinase inhibitorECOG PS 0Grade 3/4 neutropeniaHand-foot syndromePhase II trialProgression-free intervalMedian age 64Tyrosine kinase inhibitorsAnti-angiogenic propertiesECOG 0Evaluable diseaseMaintenance SNeutropenic feverNonhematologic toxicityHematologic toxicityMaintenance therapyPrimary endpointSecondary endpointsStable diseaseII trialPS 0
2006
Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer
Roy S, Russo S, Black G, Eloubeidi M, Steg A, Zelterman D, Johnson M, Diasio R, Saif M. Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. Journal Of Clinical Oncology 2006, 24: 14001-14001. DOI: 10.1200/jco.2006.24.18_suppl.14001.Peer-Reviewed Original ResearchPhase II studyLA pancreatic cancerEfficacy of capecitabinePancreatic cancerII studyTNF-alphaThymidine phosphorylaseGI bleedingDose reductionSix-month survival ratesTP/DPD ratioTNF-alpha mRNA levelsPhase IActivity of capecitabineAdvanced pancreatic cancerGrade 1 anemiaGrade 1 thrombocytopeniaNausea/vomitingPts underwent surgeryEffect of XRTConcurrent XRTStable diseaseUnderwent surgeryMedian survivalPartial response